Neutropenia and agranulocytosis in England and Wales: Incidence and risk factors
Open Access
- 21 March 2003
- journal article
- research article
- Published by Wiley in American Journal of Hematology
- Vol. 72 (4) , 248-254
Abstract
The objectives of this study were to estimate the incidence of idiosyncratic neutropenia and agranulocytosis in England and Wales and to evaluate their risk factors and outcomes. The study was conducted using data from the General Practice Research Database. All cases of idiosyncratic neutropenia or agranulocytosis were identified and the incidence was estimated. This was followed by a nested case‐control study, estimating odds ratios with drug exposure from conditional logistic regression. From 1987 to 1999, 3,224 patients with idiosyncratic neutropenia (50 with agranulocytosis) were identified. The incidences of neutropenia and agranulocytosis were estimated to be 120 and 7 cases per million people per year, respectively. The adjusted odds ratios for neutropenia were 34.7 (95% confidence interval 12.0–99.7) for current users of thyroid inhibitors, 9.5 (4.4–20.8) for users of disease‐modifying antirheumatic drugs, and 7.6 (4.9–11.9) for users of aminosalicylates. Other drugs with statistically significantly increased risks of neutropenia included antibacterial drugs, non‐opioid analgesics, NSAIDs, antidepressants, ulcer‐healing drugs, and anti‐epileptics. The increase in risk of neutropenia predominantly occurred during the first months of treatment. For most drugs investigated in this study, there was no relationship to daily dose. The excess 1‐year mortality was low among neutropenia and agranulocytosis cases and mostly explained by the underlying disease state. In conclusion, the highest risks of neutropenia were generally found in patients starting treatment. The excess 1‐year mortality was low among neutropenia and agranulocytosis cases and can be mostly explained by the underlying disease state. Am. J. Hematol. 72:248–254, 2003.Keywords
This publication has 22 references indexed in Scilit:
- Hospitalizations for Aplastic Anemia and Agranulocytosis in SaskatchewanJournal of Clinical Epidemiology, 1998
- The quality of information recorded on a UK database of primary care records: A study of hospitalizations due to hypoglycemia and other conditionsPharmacoepidemiology and Drug Safety, 1994
- Drug‐induced agranulocytosis: prognostic factors in a series of 168 episodesBritish Journal of Haematology, 1991
- Patterns of infection in 41 patients with idiosyncratic drug-induced agranulocytosisAnnals of Hematology, 1991
- Validation of information recorded on general practitioner based computerised data resource in the United Kingdom.BMJ, 1991
- Incidence and Cause of Aplastic Anemia, Hemolytic Anemia, Agranulocytosis and ThrombocytopeniaActa Medica Scandinavica, 1981
- Drug‐Induced Blood DyscrasiasActa Medica Scandinavica, 1979
- Drug‐Induced Neutropenia in the Stockholm Region 1973‐75: Frequency and CausesActa Medica Scandinavica, 1978
- MORTALITY IN AGRANULOCYTOSISThe Lancet, 1974
- DRUG‐INDUCED AGRANULOCYTOSIS, WITH SPECIAL REFERENCE TO AMINOPHENAZONEActa Medica Scandinavica, 1970